Regeneron Pharmaceuticals Balance Sheet
NASDAQ: REGNHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals financial position
At the end of fiscal 2025, Regeneron Pharmaceuticals reported total assets of $40.56 billion, up 7.4% from a year earlier against total liabilities of $9.30 billion. Shareholders' equity stood at $31.26 billion, or 77.1% of assets. The company held $3.12 billion in cash and equivalents against $1.99 billion of debt, a net cash position of $1.13 billion.
The current ratio (current assets divided by current liabilities) was 4.13, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.06.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.12B | 2.49B | 2.73B | 3.11B | 2.89B | 2.19B | 1.62B | 1.47B | 812.70M | 535.20M |
| Short-Term Investments | 5.49B | 6.52B | 8.11B | 4.64B | 2.81B | 1.39B | 1.60B | 1.34B | 596.80M | 503.48M |
| Receivables | 5.74B | 6.21B | 5.67B | 5.33B | 6.04B | 4.11B | 2.10B | 1.72B | 1.54B | 1.34B |
| Inventory | 3.20B | 3.09B | 2.58B | 2.40B | 1.95B | 1.92B | 1.42B | 1.15B | 726.10M | 399.36M |
| Total Current Assets | 18.02B | 18.66B | 19.48B | 15.88B | 14.01B | 9.78B | 7.69B | 6.45B | 4.33B | 3.18B |
| Property, Plant & Equipment | 5.12B | 4.60B | 4.15B | 3.76B | 3.48B | 3.22B | 2.89B | 2.58B | 2.36B | 2.08B |
| Intangible Assets | 1.26B | 1.15B | 1.04B | 915.50M | 6.70M | — | — | — | — | — |
| Long-Term Investments | 10.26B | 8.90B | 5.40B | 6.59B | 6.84B | 3.14B | 3.26B | 1.75B | 1.49B | 864.26M |
| Total Assets | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B | 14.81B | 11.73B | 8.76B | 6.97B |
| Accounts Payable | 939.00M | 789.50M | 606.60M | 589.20M | 564.00M | 475.50M | 418.10M | 218.20M | 178.20M | 134.98M |
| Short-Term Debt | — | — | — | — | — | — | 0 | — | — | — |
| Total Current Liabilities | 4.37B | 3.94B | 3.42B | 3.14B | 3.93B | 2.70B | 2.10B | 1.44B | 1.14B | 1.24B |
| Long-Term Debt | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 0 | — | — | — |
| Total Liabilities | 9.30B | 8.41B | 7.11B | 6.55B | 6.67B | 6.14B | 3.72B | 2.98B | 2.62B | 2.52B |
| Shareholders' Equity | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | 8.76B | 6.14B | 4.45B |
| Retained Earnings | 35.80B | 31.67B | 27.26B | 23.31B | 18.97B | 10.89B | 7.38B | 5.25B | 2.95B | 1.75B |
| Total Debt | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 0 | — | — | — |
| Net Cash (Debt) | 6.62B | 7.03B | 8.86B | 5.76B | 3.71B | 1.61B | 3.21B | 2.81B | 1.41B | 1.04B |
This table shows 10 annual periods of Regeneron Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow REGN's reporting calendar. What is a balance sheet?